Literature DB >> 19627253

Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging.

Łukasz Matusiak1, Andrzej Bieniek, Jacek C Szepietowski.   

Abstract

Hidradenitis suppurativa (HS) is a recurrent, debilitating suppurative skin disease. The major challenge is the choice of optimal treatment. Assessment of treatment effectiveness is currently associated with clinical observations of disease activity based on Hurley's or Sartorius' grading system. Detailed examination of patients with HS and evaluation of disease severity is frequently time-consuming and undoubtedly subjective. With regard to these factors, there is a need for laboratory findings that will help resolve the problem. The aim of this study was to determine the usefulness of soluble interleukin-2 receptor (sIL-2R) serum concentration as a marker of HS clinical staging and comparative analysis with the commonly conducted laboratory measurements, including white blood cell count, C-reactive protein and erythrocyte sedimentation rate. The statistical analysis of all these laboratory parameters conducted within a group of 54 individuals with HS revealed that sIL-2R serum level seems to be the most sensitive measurement for evaluation of disease stage. Moreover, the existence of strong dependences between sIL-2R serum concentration and Hurley's HS grading system were demonstrated. In conclusion, we believe that sIL-2R serum level could be used as a valuable marker for disease staging in patients with HS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19627253     DOI: 10.1080/13547500903075218

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  10 in total

Review 1.  [Acne inversa/hidradenitis suppurativa: An update].

Authors:  R Sabat; A Tsaousi; J Rossbacher; H Kurzen; T Fadai; U Schwichtenberg; S Schneider-Burrus; G Kokolakis; K Wolk
Journal:  Hautarzt       Date:  2017-12       Impact factor: 0.751

Review 2.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

Review 3.  [Acne inversa/hidradenitis suppurativa: A challenge for the future].

Authors:  R Sabat
Journal:  Hautarzt       Date:  2017-12       Impact factor: 0.751

Review 4.  A review of wide surgical excision of hidradenitis suppurativa.

Authors:  Ziyad Alharbi; Jens Kauczok; Norbert Pallua
Journal:  BMC Dermatol       Date:  2012-06-26

Review 5.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

6.  Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review.

Authors:  Samuel Der Sarkissian; Schapoor Hessam; Joslyn S Kirby; Michelle A Lowes; Dillon Mintoff; Haley B Naik; Hans Christian Ring; Nisha Suyien Chandran; John W Frew
Journal:  JAMA Dermatol       Date:  2022-03-01       Impact factor: 11.816

7.  Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.

Authors:  Afsaneh Alavi; Iltefat Hamzavi; Kurt Brown; Leandro L Santos; Zhaoyin Zhu; Huiqing Liu; Michael D Howell; Joslyn S Kirby
Journal:  Br J Dermatol       Date:  2022-03-06       Impact factor: 11.113

8.  The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa.

Authors:  D Jiménez-Gallo; R de la Varga-Martínez; L Ossorio-García; C Albarrán-Planelles; C Rodríguez; M Linares-Barrios
Journal:  Mediators Inflamm       Date:  2017-07-10       Impact factor: 4.711

9.  The Clinical Pattern of Axillary Hidradenitis Suppurativa among Saudi Arabians: Mode of Presentation and Treatment Challenges.

Authors:  Bader Hamza Shirah; Hamza Asaad Shirah
Journal:  J Cutan Aesthet Surg       Date:  2017 Apr-Jun

Review 10.  Hidradenitis suppurativa: infection, autoimmunity, or both?

Authors:  Costas A Constantinou; George E Fragoulis; Elena Nikiphorou
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-12-30       Impact factor: 5.346

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.